Berlin, 8 February 2022 – Main Capital Partners (“Main”) today announces it has backed biomedion, a leading GxP data cloud platform provider.
biomedion offers an extensive suite of software that is deployed across all “good practice” areas (“GxP”) in the life and health sciences industry, where quality guidelines and regulations are of paramount importance.
biomedion is headquartered in Berlin and has also expanded into the United States with plans to further extend its reach across Europe and North-America. biomedion represents the third investment from the Main Foundation I fund, which was launched in October 2021 and targets innovative, high-growth software companies.
biomedion enables clients in the life and health sciences industry to address its growing number of regulations, allowing customers to be continuously audit-ready in real time in compliance with “GxP” requirements (referring to quality, regulatory and clinical systems). biomedion not only serves top 20 global pharmaceutical and biosimilar companies, but also their supporting Contract Research Organisations (“CROs”) as well as emerging biotechs across Europe and North America.
Changemaker in life sciences
biomedion’s flagship application is the holistic data management platform neuronOS, which allows life and health science companies to collect raw data in a Good Laboratory Practice (GLP)-compliant manner, from hundreds or thousands of instruments within the companies’ laboratories and to store it in a secure, responsive and F.A.I.R. manner (findable, accessible, interoperable and reusable).
neuronOS ensures audit-readiness and GxP compliance anytime. To date, neuronOS is known as the only available solution in the market that truly addresses GLP raw data integrity and data preservation in GxP environments. Additionally, the availability of integrated GxP data enables new ways of AI-supported, data-driven decision-making.
Milestone for continued growth trajectory
The strategic partnership with Main symbolises the next milestone in biomedion’s continued high-growth trajectory and resilient and agile approach with the purpose of further strengthening the long-term relationship with its customers and partners. The company intends to implement a strategy of growth both organic and through acquisitions, supported by the expertise and experience of Main Capital Partners. To further advance this growth strategy, Dirk Aulike has been appointed as Chief Executive Officer (“CEO”) while Andreas Suchanek’s role will evolve to President and Chief Strategy Officer (“CSO”).
High-growth software segment benefiting from regulatory tailwinds
Main has made a substantial investment into biomedion, which represents its strong belief in the future growth prospects of Compliance Management Software for the life and health sciences industry.
While many life and health science companies still store their information in large hardware depots, biomedion’s neuronOS platform offers a slick, modern and centralised digital storage that is available in the cloud as well as on-premises via its hybrid model.
Sven van Berge Henegouwen, Head of DACH-activities at Main, commented:
“This highly attractive product-market is expected to grow by around 23% per year until 2030. We look forward to further advance in this attractive segment driven by the importance of data, and to supporting the biomedion management in their global objectives, using various a range of growth strategies.”
Dirk Aulike, CEO of biomedion, added:
“The number and complexity of regulations will only increase in the coming years and many companies are not yet equipped for this rapidly increasing scrutiny. biomedion offers an immediate solution to address and solve these requirements.”
Driving growth across Europe and in the US
Since 2003, Main has invested exclusively in rapidly growing enterprise software companies. Main has extensive experience in the healthcare software market through its investments in Enovation, SDB, Alfa eCare, Regas, RVC, and The Patient Safety Company.
Andreas Suchanek, co-founder and President of biomedion, added:
“We are very much looking forward to partnering with Main and together further strengthening our existing footprint into the EU and US, as we seek to scale up biomedion into a leading global market player. neuronOS is a powerful differentiator and a strong platform for growth, helping our clients to ensure availability and integrity of their GxP data across the entire life cycle. Ultimately, this will enable them to meet their growing compliance requirements and allows for new ways of analysing data on a larger scale.”
We will keep you informed on the most relevant developments of Main Capital Partners